Paper39350366
Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.
Jessen F and 44 others. J Prev Alzheimers Dis, 2024. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators. Papers, record 39350366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39350366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Humans | |
| Europe | |
| Amyloid beta-Peptides | |
| Antibodies, Monoclonal, Humanized | |
| Drug Development |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35379992 | New insights into the genetic etiology of Alzheimer's disease and related dementias. | Nat Genet | 2022 | https://conductscience.org/library/papers/35379992 | PubMed |
| 2 | 35676941 | Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates. | Alzheimers Dement (N Y) | 2022 | https://conductscience.org/library/papers/35676941 | PubMed |
| 3 | 37202517 | Blood biomarkers for Alzheimer's disease in clinical practice and trials. | Nat Aging | 2023 | https://conductscience.org/library/papers/37202517 | PubMed |
| 4 | 33665337 | General practitioners' attitude toward early and pre-dementia diagnosis of AD in five European countries-A MOPEAD project survey. | Alzheimers Dement (Amst) | 2021 | https://conductscience.org/library/papers/33665337 | PubMed |
| 5 | 32738937 | Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. | Lancet | 2020 | https://conductscience.org/library/papers/32738937 | PubMed |
| 6 | 35542993 | Aducanumab: Appropriate Use Recommendations Update. | J Prev Alzheimers Dis | 2022 | https://conductscience.org/library/papers/35542993 | PubMed |
| 7 | 9447441 | Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. | Int Psychogeriatr | 1997 | https://conductscience.org/library/papers/9447441 | PubMed |
| 8 | 31205802 | Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment. | Rand Health Q | 2019 | https://conductscience.org/library/papers/31205802 | PubMed |
| 9 | 33170262 | Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. | JAMA Netw Open | 2020 | https://conductscience.org/library/papers/33170262 | PubMed |
| 10 | 36376775 | The Costs of Dementia in Europe: An Updated Review and Meta-analysis. | Pharmacoeconomics | 2023 | https://conductscience.org/library/papers/36376775 | PubMed |
| 11 | 32611641 | Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium. | Neurology | 2020 | https://conductscience.org/library/papers/32611641 | PubMed |
| 12 | 37280110 | Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. | Brain | 2023 | https://conductscience.org/library/papers/37280110 | PubMed |
| 13 | 37586881 | Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. | Neurology | 2023 | https://conductscience.org/library/papers/37586881 | PubMed |
| 14 | 36130840 | β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. | Neurology | 2022 | https://conductscience.org/library/papers/36130840 | PubMed |
| 15 | 27582220 | The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. | Nature | 2016 | https://conductscience.org/library/papers/27582220 | PubMed |
| 16 | 36641605 | Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. | J Prev Alzheimers Dis | 2023 | https://conductscience.org/library/papers/36641605 | PubMed |
| 17 | 38235531 | Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK. | Br J Psychiatry | 2024 | https://conductscience.org/library/papers/38235531 | PubMed |
| 18 | 31417957 | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. | Alzheimers Dement (N Y) | 2019 | https://conductscience.org/library/papers/31417957 | PubMed |
| 19 | 34750815 | "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey. | J Am Geriatr Soc | 2022 | https://conductscience.org/library/papers/34750815 | PubMed |
| 20 | 37459141 | Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37459141 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42802831 | Locally deployed large language model for real-world lecanemab eligibility pre-screening. | Alzheimers Dement (Amst) | 2026 | https://conductscience.org/library/papers/42802831 | PubMed |
| 42711466 | Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population. | Neurol Sci | 2026 | https://conductscience.org/library/papers/42711466 | PubMed |
| 42426158 | Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe. | Sci Rep | 2026 | https://conductscience.org/library/papers/42426158 | PubMed |
| 42410071 | The Protective Effects of Small-Molecule Compound 0242 Against LPS-Induced Neuroinflammation and in P301S Tau Transgenic Mice. | Neurochem Res | 2026 | https://conductscience.org/library/papers/42410071 | PubMed |
| 41593034 | Unmasking the hidden catalyst: How infections trigger Alzheimer's disease. | J Alzheimers Dis | 2026 | https://conductscience.org/library/papers/41593034 | PubMed |
| 41113830 | Fair allocation of telemedical counseling services in early detection of Alzheimer's disease: Empirically informed ethical considerations. | Alzheimers Dement (Amst) | 2025 | https://conductscience.org/library/papers/41113830 | PubMed |
| 41102550 | Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease. | Neurol Sci | 2025 | https://conductscience.org/library/papers/41102550 | PubMed |
| 40761402 | Pharmacogenetics or predictive genetics? APOE testing blurs the lines. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40761402 | PubMed |
| 40646652 | Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer's disease. | Alzheimers Res Ther | 2025 | https://conductscience.org/library/papers/40646652 | PubMed |
| 40413561 | Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. | Alzheimers Res Ther | 2025 | https://conductscience.org/library/papers/40413561 | PubMed |
| 40370494 | Incorporating individually defined brain health priorities in clinical trial outcomes: the electronic Person-Specific Outcome Measure approach in the United States. | Alzheimers Dement (N Y) | 2025 | https://conductscience.org/library/papers/40370494 | PubMed |
| 40205115 | Impact of dementia-landscaped therapy garden on psychological well-being- A pilot study. | J Neural Transm (Vienna) | 2025 | https://conductscience.org/library/papers/40205115 | PubMed |
| 39800469 | Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease. | J Prev Alzheimers Dis | 2025 | https://conductscience.org/library/papers/39800469 | PubMed |
| 39596969 | Trends in Global Burden of Alzheimer's Disease and Other Dementias Attributable to High Fasting Plasma Glucose, 1990-2021. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39596969 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39350366
GET https://conductscience.org/api/papers/v1/39350366/authors?page=2